


The Target Discovery Institute Cellular High Throughput Screening



TARGET
DISCOVERY
INSTITUTE

Daniel Ebner
HIDI

October 1st, 2018

TDI Cellular Screening Facility & CRISPR Screening



1.

Target Discovery

TARGET DISCOVERY INSTITUTE

2.



3.

Home | Site Map | Contact | @NDMOxford | Edit |

Target Discovery Institute - TDI
Nuffield Department of Medicine

Home | About | TDI Research | Publications | Outreach | Contact | Internal

Chemical Biology | Mass Spectrometry | Medicinal Chemistry | Epigenetics | Cellular HTS | Quantitative Imaging | Pharmacogenomics
ARUK Oxford Drug Discovery Institute | Biophysics and Biochemical Screening

CRISPR/Cas 9 Cell Screening Facility

Introduction

CRISPR/Cas9 technology is ideally suited for genome-wide screening applications due to the ease of generating guide RNAs (gRNAs) and the versatility of Cas9 or Cas9 derivatives to knockout, repress, or activate expression of target genes. Several pooled lentiviral CRISPR libraries have been developed and are now publicly available. Here at the TDI we have Pooled Lentiviral CRISPR genome knockout and CRISPR gain of function libraries.

Daniel Ebner, Elena Navarro Guerrero and Dylan Jones

- Cellular HTS
 - High Throughput Screening
 - CRISPR Pooled Screening
 - CRISPR loss of function screening
 - CRISPR gain of function screening
- HTS Equipment
- HTS Readouts
- Libraries/Reagents
- Group Members
- Application and Fees
- BHF Cardiovascular Target Discovery
- News and Publications
- Contact

1. TDI Cellular HTS Screening



Home Site Map Contact @NDMOxford Edit Google Custom Search

Target Discovery Institute - TDI
Nuffield Department of Medicine

UNIVERSITY OF OXFORD

Home About TDI Research Publications Outreach Contact Internal

Chemical Biology Mass Spectrometry Medicinal Chemistry Epigenetics Cellular HTS Quantitative Imaging Pharmacogenomics
ARUK Oxford Drug Discovery Institute Biophysics and Biochemical Screening

Libraries and Reagents

Libraries



The Target Discovery Institute holds expansive RNAi libraries encompassing **siRNA**, **shRNA** and **miRNA**; in addition to diverse set and FDA approved **Small Compound Libraries**.

Our screening libraries are available as **Mouse** or **Human** species specific targets and are arrayed into targeted subsets (e.g. Oncology Drug Sets, Protein Kinase Inhibitors etc.) for efficient, target driven screening.

All libraries are available in **96** or **384** well format, suitable to your screening platform.

All reagents and libraries within these pages are available to any investigators interested in running screens. Our primary **On-Target Plus** siRNA libraries are supplied by **ThermoFisher** as pooled whole genome siRNA's and custom designed "druggable" siRNA libraries.

Reagents

In addition to our RNAi libraries we have access to a large number of [Transfection Reagents](#) suitable for RNAi screening applications.

For High Content Imaging we have access to wide range of stains and protocols. Click for more information on [High Content Imaging](#) and the [range of stains](#) available.

For further information about any of the TDI libraries, Transfection Reagents, High Content Imaging and Stains; or for more information about any aspect of Screening, please contact [Daniel Ebner](#).

- Cellular HTS
 - [High Throughput Screening](#)
 - [CRISPR Pooled Screening](#)
 - [HTS Equipment](#)
 - [HTS Readouts](#)
 - [Libraries/Reagents](#)
 - [siRNA Libraries](#)
 - [shRNA Libraries](#)
 - [Small Compound Libraries](#)
 - [cDNA Libraries](#)
 - [Transfection Reagent Panel](#)
- [Group Members](#)
- [Application and Fees](#)
- [BHF Cardiovascular Target Discovery](#)
- [News and Publications](#)
- [Contact](#)

Libraries/Reagents

- [siRNA Libraries](#)
- [shRNA Libraries](#)
- [Small Compound Libraries](#)
- [cDNA Libraries](#)
- [Transfection Reagent Panel](#)

<http://www.tdi.ox.ac.uk/high-throughput-screening>

If you are interested in initiating a screen, just send me an email:

daniel.ebner@ndm.ox.ac.uk





© 2017 Offices of the Nuffield Professor of Medicine, Nuffield Department of Medicine, University of Oxford
Henry Wellcome Building for Molecular Physiology, Old Road Campus, Headington, Oxford OX3 7BN


Driven by [Newt](#), Powered by [Pinfox](#)



[Home](#) | [Site Map](#) | [Contact](#) | [Freedom of Information](#) | [Privacy Policy](#) | [Copyright](#) | [Accessibility](#)
[Medical Sciences Division](#) | [Oxford University](#)




"The retinoid agonist Tazarotene promotes angiogenesis and wound regeneration" ZEN - RDM



"A genome-wide IR-induced RAD51 foci RNAi screen identifies CDC73 involved in chromatin remodeling for DNA repair" Helleday – Oncology




"Functional HTS to identify microRNAs regulating EMT in prostate cancer" Edwards / Rao - NDS




"Negative autoregulation of BMP dependent transcription by SIN3B splicing reveals a role for RBM39." Faherty et al., Bhattachary - RDM


Snapshot of TDI Cellular HTS Outputs




"Neuroblast Spheroid Migration" Ducker, Millar



"Systematic Functional Characterization of Candidate Causal Genes for Type 2 Diabetes Risk Variants" Thomsen, Ceroni,




"Benzimidazoles promote anti-TNF induced regulatory macrophage formation and potentiate therapeutic effect in vivo model of IBD" Wildenberg - Academic Medical Center, Amsterdam



"BET inhibition as a new strategy for the treatment of gastric cancer" Montenegro et al. Müller – TDI/SGC

2. NPSC / PDi Drug Discovery Initiative





<http://npsc.ac.uk/>

This is an open call for phenotypic assay proposals funded by the Phenomics Discovery Initiative (PDi). PDi is a public-private partnership between industrial pharmaceutical companies and NPSC. PDi seeks to identify, develop, screen and validate innovative phenotypic assays that are relevant to human disease.

Selected proposals are screened free of charge.
The deadline for the next round of selections is Autumn 2017 (date TBD).

Find out more about PDi: *We use the EU commission definition of SME that can be found here.



Immuno-oncology open call, Oct 31st



<http://npsc.ac.uk/open-assay-calls>



Submit Assay Work with us Gallery Newsletter Search

About Phenotypic Screening Facilities People PDI Open Assay Calls News Contact

Open Assay Calls



This is an open call for phenotypic assay proposals funded by the Phenomics Discovery Initiative (PDI). PDI is a public-private partnership between industrial pharmaceutical companies and NPSIC. PDI seeks to identify, develop, screen and validate innovative phenotypic assays that are relevant to human disease.

Selected proposals are screened free of charge.
The deadline for the next round of selections is Autumn 2017 (date TBC).
For more news about PDI, please visit the communications dashboard of NPSIC that can be found here.

Call Guidelines Bio-Seq Cell Lines 3D Cell Culture IBD Omics Tug-Cells L1T Immunoblotting

How to apply?

Phenotypic assays are recruited from academic, clinical and SME communities through an online application portal.

Assessments for an earlier stage of development from an early clinical trial or commercial trial will also be carefully analysed and selected by the PDI scientific committee, subject to evidence of a potential industry and academic partners. Important characteristics for selection are:

- Phenotypic assays that accurately **model the complexity of the tumour microenvironment**. These should allow screening to be carried out in more relevant immune contexts, and be more representative of the pathophysiology of the disease.
- Novel assays for intracellular (or even extracellular) **immune-regulatory mechanisms** that cannot be targeted by current monoclonal antibody-based approaches. These assays should help broaden the potential mechanisms that can be targeted by new therapies.
- Assays that allow the discovery of small molecules that **synergise with known therapeutics** (biologics or CAR-T) to extend their scope and efficacy.
- Models for immunologically **“warming” up “cold” tumours**, including ones involving infiltration of 3D tumour spheroids by T cells. It is expected that these models will be complex in order to accurately represent the disease model.
- Models that can explore novel ways of **activating exhausted intra-tumoral T cells**.
- Models involving the manipulation of immunosuppressive Treg cells and/or key cytokines.
- Assays that involve other **immunosuppressive cell types** (for example, MDSCs, dendritic cells and TAMs).
- Models that could uncover new targets in **innate immune system** cell types (eg. NK cells, dendritic cells and macrophages).

3. Oxford CRISPR/Cas9 Screening Facility



Home | Site Map | Contact | @NDMOxford | Edit | Google™ Custom Search

 **Target Discovery Institute - TDI**
Nuffield Department of Medicine

UNIVERSITY OF OXFORD

Home About **TDI Research** Publications Outreach Contact Internal

Chemical Biology Mass Spectrometry Medicinal Chemistry Epigenetics Cellular HTS Quantitative Imaging Pharmacogenomics
ARUK Oxford Drug Discovery Institute Biophysics and Biochemical Screening

CRISPR/Cas 9 Cell Screening Facility








Introduction



CRISPR/Cas9 technology is ideally suited for genome-wide screening applications due to the ease of generating guide RNAs (gRNAs) and the versatility of Cas9 or Cas9 derivatives to knockout, repress, or activate expression of target genes. Several pooled lentiviral CRISPR libraries have been developed and are now publicly available. Here at the TDI we have Pooled Lentiviral CRISPR genome knockout and CRISPR gain of function libraries.

Daniel Ebner, Elena Navarro Guerrero and Dylan Jones

- Cellular HTS
 - High Throughput Screening
 - CRISPR Pooled Screening**
 - CRISPR loss of function screening
 - CRISPR gain of function screening
 - HTS Equipment
 - HTS Readouts
 - Libraries/Reagents
 - Group Members
 - Application and Fees
 - BHF Cardiovascular Target Discovery
 - News and Publications
 - Contact

-  Toronto KnockOut (TKO) CRISPR Library - Version 3
(Pooled Library #90294)
-  Human CRISPR Knockout Pooled Library (GeCKO v2)
(Pooled Library #1000000048, #1000000049)
-  Human Genome-wide CRISPRi-v2 Libraries
(Pooled Libraries #83969, #1000000090)
-  Mouse CRISPR Activation Library (SAM - 3 plasmid system)
(Pooled Library #1000000075)
-  Mouse Genome-wide CRISPRa-v2 Libraries
(Pooled Libraries #83996, #1000000093)

A quick review of CRISPR/Cas9 Screening and iPSCs:




iPSCs are derived by reprogramming somatic cells of patient donors to obtain stem cell lines that retain the genetic background of the donor and have a normal karyotype, yet can replicate indefinitely and be instructed to differentiate into a wide variety of cell types.

Target Discovery Institute Cell Screening Facility Personnel


Nuffield Department of Medicine



CRISPR Cas9 Screening Facility



CRISPR/Cas9 LOF and GOF Screening
Arrayed CRISPR Screening Development



TDI Cellular Screening Facility



Oncology Screening

Students/Visiting Fellows

Co-supervised Student – RDM/OCDEM
Functional Genomics of T2D



Junior Research Fellow – 3D Oncology



NPSC/PDi



PDi Image Analysis Specialist



Cellular HTS



ODDI Neurodegeneration Assay
Development Platform